MENLO PARK, Calif.--(BUSINESS WIRE)--Jan. 4, 2006--Depomed, Inc. (Nasdaq:DEPO) today announced statistically significant safety and efficacy benefits of its Gabapentin GR extended release tablets to treat patients with postherpetic neuralgia, a long-lasting pain condition caused by nerve damage during a shingles, or herpes zoster, viral infection. The randomized, double-blind, placebo controlled trial involved 158 postherpetic neuralgia patients. Patients were randomized to one of three treatment groups over four weeks of treatment: placebo and 1800 mg total daily dose of Gabapentin GR given once- and twice-daily.
